Literature DB >> 2309824

Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma.

T O Wilson1, K C Podratz, T A Gaffey, G D Malkasian, P C O'Brien, J M Naessens.   

Abstract

A retrospective review of 388 patients who presented to the Mayo Clinic for treatment of endometrial carcinoma between 1979 and 1983 was performed and the surgical and pathologic observations were documented. An uncommon histologic subtype was detected in 52 patients (13%): 20 adenosquamous, 14 serous papillary, 11 clear cell, 7 undifferentiated. In contrast to the survival of patients with endometrioid lesions (92%), the overall survival in these patients was only 33%. Each of the individual abnormal histologic subtypes exhibited a survival of less than 50%. At the time of surgical staging, 62% of patients with unfavorable histologic subtypes had extrauterine spread of disease. Despite liberal utilization of postoperative adjuvant therapy in 42 of the 52 patients (81%), only 10% of these patients survived 5 years. Fifty-five percent had a component of recurrence outside of the abdominal/pelvic cavity. Subsequent treatment considerations should incorporate regimens addressing systemic and local tissue control.

Entities:  

Mesh:

Year:  1990        PMID: 2309824     DOI: 10.1016/0002-9378(90)90399-r

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Comprehensive surgical staging for endometrial cancer.

Authors:  Bunja Rungruang; Alexander B Olawaiye
Journal:  Rev Obstet Gynecol       Date:  2012

2.  Abdominal wall metastasis of uterine papillary serous carcinoma in a post-menopausal woman: a case report.

Authors:  Jung-Woo Park; Sung-Ook Hwang
Journal:  J Menopausal Med       Date:  2014-04-28

Review 3.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

4.  Definitive radiotherapy for medically inoperable early-stage serous and clear cell uterine carcinoma.

Authors:  Emma C Batchelor; John M Watkins; Joseph M Jenrette
Journal:  Radiat Med       Date:  2007-12-25

Review 5.  Staging of carcinoma of the uterine cervix and endometrium.

Authors:  Takashi Koyama; Ken Tamai; Kaori Togashi
Journal:  Eur Radiol       Date:  2007-01-12       Impact factor: 7.034

6.  Utility of Preoperative CA125 Assay in the Management Planning of Women Diagnosed with Uterine Cancer.

Authors:  N Povolotskaya; N Das; K Dhar; D Brinkmann; F Gardner; R Woolas
Journal:  Surg Res Pract       Date:  2014-02-27

7.  Understanding the role of indoleamine-2,3-dioxygenase and stromal differentiation in rare subtype endometrial cancer.

Authors:  Dongling Wu; Sean Hacking; Jin Cao; Mansoor Nasim
Journal:  Rare Tumors       Date:  2021-12-07

8.  Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer.

Authors:  Benjamin B Albright; Jonathan D Black; Rachel Passarelli; Stefan Gysler; Margaret Whicker; Gary Altwerger; Gulden Menderes; Natalia Buza; Pei Hui; Alessandro D Santin; Masoud Azodi; Dan-Arin Silasi; Elena S Ratner; Babak Litkouhi; Peter E Schwartz
Journal:  Gynecol Oncol Rep       Date:  2018-01-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.